跳至主要内容
临床试验/JPRN-UMIN000039994
JPRN-UMIN000039994已完成未知

ong-term follow-up of the multicenter clinical trial using cultivated autologous corneal epithelium (EYE-01M) transplantation for patients with limbal stem-cell deficiency - Long-term follow-up of the multicenter clinical trial using cultivated autologous corneal epithelium (EYE-01M) transplantation for patients with limbal stem-cell deficiency

Japan Tissue Engineering Co., Ltd.0 个研究点目标入组 10 人开始时间: 2020年3月31日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients planning to participate in other clinical trials during the study participation 2) Patients who desire pregnancy during clinical studies 3) Patients determined to be inappropriate by physicians

研究者

相似试验

已完成
不适用
ong-term follow-up of the multicenter investigator-initiated clinical trial using cultivated autologous oral mucosal epithelial cell sheet (COMET01) transplantation for patients with limbal stem-cell deficiency
JPRN-UMIN000039992Japan Tissue Engineering Co., Ltd.6
进行中(未招募)
不适用
ong-term follow-up (up to 3 years) to investigate the maintenance of efficacy and safety of AllerT, a drug based on modified peptides of Bet V 1, applied in two different dosages to subjects suffering from birch pollen allergy during the trial AN004Tong-term follow-up of desensitization by Specific ImmunoTherapy (SIT) received during the trial AN004T in subjects allergic to birch pollenMedDRA version: 16.1Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 100000004870
EUCTR2013-003881-15-SEAnergis SA238
进行中(未招募)
1 期
ong-term follow-up (up to 3 years) to investigate the maintenance of efficacy and safety of AllerT, a drug based on modified peptides of Bet V 1, applied in two different dosages to subjects suffering from birch pollen allergy during the trial AN004Tong-term follow-up of desensitization by Specific ImmunoTherapy (SIT) received during the trial AN004T in subjects allergic to birch pollenMedDRA version: 16.1Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 100000004870
EUCTR2013-003881-15-DKAnergis SA238
进行中(未招募)
不适用
ong-term follow-up (up to 3 years) to investigate the maintenance of efficacy and safety of AllerT, a drug based on modified peptides of Bet V 1, applied in two different dosages to subjects suffering from birch pollen allergy during the trial AN004T
EUCTR2013-003881-15-LTAnergis SA238
进行中(未招募)
不适用
ong-term follow-up (up to 3 years) to investigate the maintenance of efficacy and safety of AllerT, a drug based on modified peptides of Bet V 1, applied in two different dosages to subjects suffering from birch pollen allergy during the trial AN004Tong-term follow-up of desensitization by Specific ImmunoTherapy (SIT) received during the trial AN004T in subjects allergic to birch pollenMedDRA version: 16.1Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 100000004870
EUCTR2013-003881-15-LVAnergis SA238